Recancostat compositum (R) therapy does not prevent tumor progression in young cancer patients

Authors
Bode, U Hasan, C Hulsmann, B Fleischhack, G
Citation
U. Bode et al., Recancostat compositum (R) therapy does not prevent tumor progression in young cancer patients, KLIN PADIAT, 211(4), 1999, pp. 353-355
Citations number
9
Categorie Soggetti
Pediatrics
Journal title
KLINISCHE PADIATRIE
ISSN journal
03008630 → ACNP
Volume
211
Issue
4
Year of publication
1999
Pages
353 - 355
Database
ISI
SICI code
0300-8630(199907/08)211:4<353:RC(TDN>2.0.ZU;2-Z
Abstract
Stimulated by the public discussion about an antimalignant effect of the su pplement drug Recancostat compositum(R) the drug was given in high doses to 16 young patients with intensively pretreated and measurable solid tumors for 1-30 weeks. In all patients the disease progressed, and they died 1-48 weeks following the start of the therapy. Side effects were not seen. This observation does not support the claim of an antitumor effect of Recancosta t compositum(R).